Nanomaterials for Cancer Photothermal Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (10 November 2021) | Viewed by 5736

Special Issue Editor


E-Mail Website
Guest Editor
CICS-UBI – Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal
Interests: nanomaterials; photothermal therapy; drug delivery; graphene; tissue engineering

Special Issue Information

Dear Colleagues,

Nanomaterials with specific properties can reach the tumor site and produce, upon interaction with laser radiation, a temperature increase that can damage cancer cells. For this purpose, NIR light (750–1000 nm) is generally used due to its minimal interaction with biological components (e.g., water, melanin, hemoglobin, collagen), ensuring a high tissue penetration depth and reduced off-target heating. Hence, nanomaterials with a high NIR absorption (e.g., gold nanorods, graphene derivatives, transition metal dichalcogenides) have been extensively investigated for cancer photothermal therapy. On the other hand, the assembly of nanostructures with NIR-absorbing materials (e.g., ICG, IR780, polydopamine, polypyrrole) has also been explored. The nanomaterials’ photoinduced heat can also trigger other events (e.g., endosomal escape, release of encapsulated agents), opening a venue for combining nanomaterials’ mediated photothermal therapy with other therapeutic modalities (e.g., chemotherapy, gene delivery, immunotherapy).

This Special Issue of Pharmaceutics focuses on nanomaterials aimed for cancer photothermal therapy. Research articles covering the synthesis/formulation of novel NIR-light-responsive nanomaterials, their functionalization and characterization, as well as their application in cancer combination therapy are welcome. Comprehensive reviews and progress reports covering the recent advances in this field are also welcomed.

Dr. Duarte De Melo-Diogo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • photothermal therapy
  • NIR-light-absorbing small molecules
  • NIR-light-absorbing nanomaterials
  • chemo-photothermal therapy
  • photodynamic-photothermal therapy
  • combination photothermal therapy
  • 2D nanomaterials
  • nanoparticles

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 12200 KiB  
Article
Evaluation of the Targeting and Therapeutic Efficiency of Anti-EGFR Functionalised Nanoparticles in Head and Neck Cancer Cells for Use in NIR-II Optical Window
by Teklu Egnuni, Nicola Ingram, Ibrahim Mirza, P. Louise Coletta and James R. McLaughlan
Pharmaceutics 2021, 13(10), 1651; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13101651 - 09 Oct 2021
Cited by 4 | Viewed by 2380
Abstract
Gold nanoparticles have been indicated for use in a diagnostic and/or therapeutic role in several cancer types. The use of gold nanorods (AuNRs) with a surface plasmon resonance (SPR) in the second near-infrared II (NIR-II) optical window promises deeper anatomical penetration through increased [...] Read more.
Gold nanoparticles have been indicated for use in a diagnostic and/or therapeutic role in several cancer types. The use of gold nanorods (AuNRs) with a surface plasmon resonance (SPR) in the second near-infrared II (NIR-II) optical window promises deeper anatomical penetration through increased maximum permissible exposure and lower optical attenuation. In this study, the targeting and therapeutic efficiency of anti-epidermal growth factor receptor (EGFR)-antibody-functionalised AuNRs with an SPR at 1064 nm was evaluated in vitro. Four cell lines, KYSE-30, CAL-27, Hep-G2 and MCF-7, which either over- or under-expressed EGFR, were used once confirmed by flow cytometry and immunofluorescence. Optical microscopy demonstrated a significant difference (p < 0.0001) between targeted AuNRs (tAuNRs) and untargeted AuNRs (uAuNRs) in all four cancer cell lines. This study demonstrated that anti-EGFR functionalisation significantly increased the association of tAuNRs with each EGFR-positive cancer cell. Considering this, the MTT assay showed that photothermal therapy (PTT) significantly increased cancer cell death (>97%) in head and neck cancer cell line CAL-27 using tAuNRs but not uAuNRs, apoptosis being the major mechanism of cell death. This successful targeting and therapeutic outcome highlight the future use of tAuNRs for molecular photoacoustic imaging or tumour treatment through plasmonic photothermal therapy. Full article
(This article belongs to the Special Issue Nanomaterials for Cancer Photothermal Therapy)
Show Figures

Figure 1

15 pages, 3958 KiB  
Article
In Vitro and In Vivo Evaluation of PEGylated Starch-Coated Iron Oxide Nanoparticles for Enhanced Photothermal Cancer Therapy
by Reeju Amatya, Seungmi Hwang, Taehoon Park, Kyoung Ah Min and Meong Cheol Shin
Pharmaceutics 2021, 13(6), 871; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13060871 - 12 Jun 2021
Cited by 16 | Viewed by 2745
Abstract
Iron oxide nanoparticles (IONPs) possess versatile utility in cancer theranostics, thus, they have drawn enormous interest in the cancer research field. Herein, we prepared polyethylene glycol (PEG)-conjugated and starch-coated IONPs (“PEG–starch–IONPs”), and assessed their applicability for photothermal treatment (PTT) of cancer. The prepared [...] Read more.
Iron oxide nanoparticles (IONPs) possess versatile utility in cancer theranostics, thus, they have drawn enormous interest in the cancer research field. Herein, we prepared polyethylene glycol (PEG)-conjugated and starch-coated IONPs (“PEG–starch–IONPs”), and assessed their applicability for photothermal treatment (PTT) of cancer. The prepared PEG–starch–IONPs were investigated for their physical properties by transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), X-ray diffraction (XRD), Fourier transform infrared (FT-IR) spectroscopy, and dynamic light scattering (DLS). The pharmacokinetic study results showed a significant extension in the plasma half-life by PEGylation, which led to a markedly increased (5.7-fold) tumor accumulation. When PEG–starch–IONPs were evaluated for their photothermal activity, notably, they displayed marked and reproducible heating effects selectively on the tumor site with laser irradiation. Lastly, efficacy studies demonstrated that PEG–starch–IONPs-based PTT may be a promising mode of cancer therapy. Full article
(This article belongs to the Special Issue Nanomaterials for Cancer Photothermal Therapy)
Show Figures

Graphical abstract

Back to TopTop